Overview

  • Product name
    Anti-MMP2 antibody [EPR17003-25]
    See all MMP2 primary antibodies
  • Description
    Rabbit monoclonal [EPR17003-25] to MMP2
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment within Mouse MMP2 aa 100-300. The exact sequence is proprietary.
    Database link: P33434

  • Positive control
    • IP: HT1080 whole cell lysate. WB: Human, mouse and rat plasma lysates; Rat serum lysate; Mouse and rat lung lysates; HT1080 whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab181286 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 74 kDa (predicted molecular weight: 73 kDa).
IP 1/30.

Target

  • Function
    Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-
    -Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro.
    PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.
  • Tissue specificity
    Produced by normal skin fibroblasts. PEX is expressed in a number of tumors including gliomas, breast and prostate.
  • Involvement in disease
    Defects in MMP2 are the cause of Torg-Winchester syndrome (TWS) [MIM:259600]; also known as multicentric osteolysis nodulosis and arthropathy (MONA). TWS is an autosomal recessive osteolysis syndrome. It is severe with generalized osteolysis and osteopenia. Subcutaneous nodules are usually absent. Torg-Winchester syndrome has been associated with a number of additional features including coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. However, these features are not always present and have occasionally been observed in other osteolysis syndromes.
  • Sequence similarities
    Belongs to the peptidase M10A family.
    Contains 3 fibronectin type-II domains.
    Contains 4 hemopexin-like domains.
  • Domain
    The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Post-translational
    modifications
    Phosphorylation on multiple sites modulates enzymatic activity. Phosphorylated by PKC in vitro.
    The propeptide is processed by MMP14 (MT-MMP1) and MMP16 (MT-MMP3). Autocatalytic cleavage in the C-terminal produces the anti-angiogenic peptide, PEX. This processing appears to be facilitated by binding integrinv/beta3.
  • Cellular localization
    Secreted > extracellular space > extracellular matrix. Membrane. Nucleus. Colocalizes with integrin alphaV/beta3 at the membrane surface in angiogenic blood vessels and melanomas. Found in mitochondria, along microfibrils, and in nuclei of cardiomyocytes.
  • Information by UniProt
  • Database links
  • Alternative names
    • 72 kDa gelatinase antibody
    • 72kD type IV collagenase antibody
    • CLG 4 antibody
    • CLG 4A antibody
    • CLG4 antibody
    • CLG4A antibody
    • Collagenase Type 4 alpha antibody
    • Collagenase type IV A antibody
    • Gelatinase A antibody
    • Gelatinase alpha antibody
    • Gelatinase neutrophil antibody
    • Matrix metallopeptidase 2 gelatinase A 72kDa gelatinase 72kDa type IV collagenase antibody
    • Matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) antibody
    • Matrix Metalloproteinase 2 antibody
    • Matrix metalloproteinase II antibody
    • Matrix metalloproteinase-2 antibody
    • MMP 2 antibody
    • MMP II antibody
    • MMP-2 antibody
    • MMP2 antibody
    • MMP2_HUMAN antibody
    • MONA antibody
    • Neutrophil gelatinase antibody
    • PEX antibody
    • TBE 1 antibody
    • TBE-1 antibody
    see all

Images

  • MMP2 was immunoprecipitated from 0.35 mg HT1080 (human fibrosarcoma cell line) whole cell lysate with ab181286 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab181286 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

    Lane 1: HT1080 whole cell lysate 10 µg (Input).
    Lane 2: ab181286 IP in HT1080 whole cell lysate (+).
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab181286 in HT1080 whole cell lysate (-).

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 minutes.

  • Lanes 1-5 : Anti-MMP2 antibody [EPR17003-25] (ab181286) at 1/1000 dilution
    Lanes 6-7 : Anti-MMP2 antibody [EPR17003-25] (ab181286) at 1/2000 dilution

    Lane 1 : Mouse plasma lysate at 20 µg
    Lane 2 : Rat serum lysate at 20 µg
    Lane 3 : Mouse lung lysate at 20 µg
    Lane 4 : Rat plasma lysate at 20 µg
    Lane 5 : Rat lung lysate at 20 µg
    Lane 6 : HT1080 (human fibrosarcoma cell line) whole cell lysate at 10 µg
    Lane 7 : Human plasma lysate at 10 µg

    Secondary
    All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

    Predicted band size: 73 kDa
    Observed band size: 72 kDa
    why is the actual band size different from the predicted?



    Exposure time: Lanes 1-2: 3 minutes; Lanes 3-5: 10 seconds; Lanes 6-7: 30 seconds.

    Blocking/Dilution buffer: 5% NFDM/TBST.

     

     

References

ab181286 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab181286.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up